150 related articles for article (PubMed ID: 36382911)
1. Carbon-11-Labeled Methionine PET/CT in Patients With FDG-Occult Multiple Myeloma: A Prospective Pilot Study.
Wang Y; Yee A; Bernstein Z; O'Donnell E; Raje N; Mahmood U
AJR Am J Roentgenol; 2023 Apr; 220(4):578-579. PubMed ID: 36382911
[TBL] [Abstract][Full Text] [Related]
2. Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by
Heidemeier A; Schloetelburg W; Thurner A; Metz C; Heidemeier H; Rasche L; Martin Kortuem K; Boeckle D; Weiland E; Benkert T; Nickel D; Werner R; Buck AK; Bley TA
Eur J Radiol; 2022 Oct; 155():110493. PubMed ID: 36027759
[TBL] [Abstract][Full Text] [Related]
3. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.
Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A
Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383
[TBL] [Abstract][Full Text] [Related]
4. [PET/CT with 18F-fluorodeoxyglucose and 11C-methionine after autologous stem cell transplantation in multiple myeloma patients].
Solovev MV; Mendeleeva LP; Firsova MV; Aslanidi IP; Mukhortova OV; Savchenko VG
Ter Arkh; 2019 Jul; 91(7):75-82. PubMed ID: 32598739
[TBL] [Abstract][Full Text] [Related]
5. Comparison of [
Stokke C; Nørgaard JN; Feiring Phillips H; Sherwani A; Nuruddin S; Connelly J; Schjesvold F; Revheim ME
Mol Imaging Biol; 2022 Oct; 24(5):842-851. PubMed ID: 35501622
[TBL] [Abstract][Full Text] [Related]
6. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.
Cassou-Mounat T; Balogova S; Nataf V; Calzada M; Huchet V; Kerrou K; Devaux JY; Mohty M; Talbot JN; Garderet L
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1995-2004. PubMed ID: 27121691
[TBL] [Abstract][Full Text] [Related]
7.
Morales-Lozano MI; Rodriguez-Otero P; Sancho L; Nuñez-Cordoba JM; Prieto E; Marcos-Jubilar M; Rosales JJ; Alfonso A; Guillen EF; San-Miguel J; Garcia-Velloso MJ
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077292
[TBL] [Abstract][Full Text] [Related]
8. Improved Detection of Minimal Residual Disease by 11C-Methionine PET/CT in a Young Patient With Unusual Extramedullary Presentation of Recurrent Multiple Myeloma.
Caldarella C; Annunziata S; Pagano L; De Stefano V; Rufini V
Clin Nucl Med; 2017 Feb; 42(2):e130-e134. PubMed ID: 27922862
[TBL] [Abstract][Full Text] [Related]
9.
Hemrom A; Tupalli A; Alavi A; Kumar R
PET Clin; 2022 Jul; 17(3):415-430. PubMed ID: 35717100
[TBL] [Abstract][Full Text] [Related]
10. 11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement.
Lapa C; Knop S; Schreder M; Rudelius M; Knott M; Jörg G; Samnick S; Herrmann K; Buck AK; Einsele H; Lückerath K
Theranostics; 2016; 6(2):254-61. PubMed ID: 26877783
[TBL] [Abstract][Full Text] [Related]
11. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
Chen M; Zhu W; Du J; Yang C; Han B; Zhou D; Huo L; Zhuang J
Sci Rep; 2021 Nov; 11(1):22188. PubMed ID: 34773054
[TBL] [Abstract][Full Text] [Related]
12. Clinical application of combination [
Wang Z; Feng Z; Zhu D; Wang X; Chen J; Zhu Y; Wang H
BMC Endocr Disord; 2024 Feb; 24(1):19. PubMed ID: 38311763
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. F-18 FDG PET/CT and F-18 FLT PET/CT as predictors of outcome in patients with multiple myeloma. A pilot study.
Gallicchio R; Nardelli A; Calice G; Guarini A; Guglielmi G; Storto G
Eur J Radiol; 2021 Mar; 136():109564. PubMed ID: 33517249
[TBL] [Abstract][Full Text] [Related]
15. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.
Nanni C; Zamagni E; Farsad M; Castellucci P; Tosi P; Cangini D; Salizzoni E; Canini R; Cavo M; Fanti S
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):525-31. PubMed ID: 16453155
[TBL] [Abstract][Full Text] [Related]
16. [Clinical value of 18F-FDG-PET and 11C-MET-PET in patients with plasma cell malignancy].
Kobayashi M; Yamashita K; Takaori-Kondo A
Nihon Rinsho; 2015 Jan; 73(1):74-9. PubMed ID: 25626308
[TBL] [Abstract][Full Text] [Related]
17. The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma.
Sager S; Ergül N; Ciftci H; Cetin G; Güner SI; Cermik TF
Skeletal Radiol; 2011 Jul; 40(7):843-7. PubMed ID: 21229354
[TBL] [Abstract][Full Text] [Related]
18. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
19. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
Jamet B; Zamagni E; Nanni C; Bailly C; Carlier T; Touzeau C; Michaud AV; Moreau P; Bodet-Milin C; Kraeber-Bodere F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751375
[TBL] [Abstract][Full Text] [Related]
20. Clinical Value of FDG-PET/CT in Multiple Myeloma: An Update.
Bezzi D; Ambrosini V; Nanni C
Semin Nucl Med; 2023 May; 53(3):352-370. PubMed ID: 36446644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
